Diagenode

Drug-tunable multidimensional synthetic gene control using inducible degron-tagged dCas9 effectors


Kleinjan D.A. et al.

The nuclease-deactivated variant of CRISPR-Cas9 proteins (dCas9) fused to heterologous transactivation domains can act as a potent guide RNA sequence-directed inducer or repressor of gene expression in mammalian cells. In such a system the long-term presence of a stable dCas9 effector can be a draw-back precluding the ability to switch rapidly between repressed and activated target gene expression states, imposing a static environment on the synthetic regulatory circuits in the cell. To address this issue we have generated a toolkit of conditionally degradable or stabilisable orthologous dCas9 or Cpf1 effector proteins, thus opening options for multidimensional control of functional activities through combinations of orthogonal, drug-tunable artificial transcription factors.

Tags
Antibody

Share this article

Published
October, 2017

Source

Products used in this publication

  • Antibody cas9 icon
    C15310259-100
    S. aureus CRISPR/Cas9 polyclonal antibody (C-te...

       Site map   |   Contact us   |   Conditions of sales   |   Conditions of purchase   |   Privacy policy   |   Diagenode Diagnostics